Kelly Nuckley
Psychiatric/Mental Health · Metairie, LANPI 1194365114
Payments from drug & device makers
Across 159 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$735
- Johnson & Johnson$495
- Alkermes, Inc.$436
- Teva Pharmaceuticals USA, Inc.$358
- Otsuka America Pharmaceutical, Inc.$235
- Neurocrine Biosciences, Inc.$161
- plus $594 from 8 others
What the payments were for
- Food & beverage$3,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $735 |
| Johnson & Johnson | 26 | $495 |
| Alkermes, Inc. | 28 | $436 |
| Teva Pharmaceuticals USA, Inc. | 21 | $358 |
| Otsuka America Pharmaceutical, Inc. | 14 | $235 |
| Neurocrine Biosciences, Inc. | 7 | $161 |
| Vanda Pharmaceuticals Inc. | 6 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $134 |
| Indivior Inc. | 4 | $103 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Lundbeck LLC | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Eisai Inc. | 2 | $29 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,014 in reported general payments places this provider in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 29 | $88,166 |
| TrintellixVortioxetine Hydrobromide | 16 | $9,606 |
| Duloxetine Hcl | 45 | $2,209 |
| Mirtazapine | 38 | $1,160 |
| Trazodone Hcl | 81 | $803 |
| Hydroxyzine Pamoate | 43 | $708 |
| Quetiapine Fumarate | 41 | $669 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $655 |
| Aripiprazole | 40 | $623 |
| Buspirone Hcl | 44 | $547 |
| Gabapentin | 26 | $469 |
| Lamotrigine | 24 | $457 |
| Fluoxetine Hcl | 43 | $400 |
| Risperidone | 17 | $357 |
| Amitriptyline Hcl | 12 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $235 | $88,16629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Metairie
- Marianne CallMetairie$12K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.